Hyperhomocysteinaemia and vascular disease

Blood Reviews

Volumn 12, Issue 1, 1998, Pages 23-34

  Townend, J ^a   O'Sullivan, J ^a   Wilde, J T ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; METHIONINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTERY DISEASE; BLOOD CLOTTING; CYANOCOBALAMIN DEFICIENCY; FOLIC ACID DEFICIENCY; HUMAN; HYPERHOMOCYSTEINEMIA; METHYLATION; PRIORITY JOURNAL; PYRIDOXINE DEFICIENCY; REVIEW; THROMBOCYTE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

EID: 0031950397     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(98)90027-3     Document Type: Article

References (90)

1. Mudd SH, Skovby F, Levy HL et al. The natural history of homocysteinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
2. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1: 228-237.
3. Finkelstein JD, Martin JJ. Methionine metabolism in mammals: adaptation to methionine excess. J Biol Chem 1986; 261: 1582-1587.
4. Jencks DA, Matthews RG. Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine: effect of adenosylmethionine and NADPH on the equilibrium between active and inactive forms of the enzyme and on the kinetics of approach to equilibrium. J Biol Chem 1987; 262: 2485-2493.
5. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992; 200: 218-229.
6. Ubbink JB, Vermaak WJH, Vandermerwe A, Becker PJ. The effect of blood sample aging and food consumption on plasma total homocysteine levels. Clin Chim Acta 1992; 207: 119-128.
7. Malinow MR, Axhelm MK, Meredith MJ, Macdonald NA, Upson BM. Synthesis and transsulfuration of homocysteine in blood. J Lab Clin Med 1994; 123: 421-429.
8. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1764-1779.
9. Jacobsen DW, Gatautis VJ, Green R et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994; 40: 873-881.
10. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr (ed). Atherosclerotic Cardiovascular Disease, Hemostasis and Endothelial Function. New York: Marcel Dekker 1992: 183-236.
11. Kraus JP. Molecular basis of phenotype expression in homocysteinuria. J Inherit Metab Dis 1994; 17: 383-390.
12. Kluijtmans LAJ, Blom HJ, Boers GHJ, van Oost BA, Trijbels FJM, van den Heuvel LPWJ. Two novel missense mutations in the cystathionine beta-synthase gene in homocystinuric patients. Hum Genet 1995; 96: 249-250.
13. Boers GHJ, Smals AHG, Trijbels FJM et al. Heterozygosity for homocystinuria in premature peripheral and cerebral oclusive arterial disease. N Eng J Med 1985; 313: 709-715.
14. Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Eng J Med 1991; 324: 1149-1155.
15. Erbe RW. Inborn errors of folate metabolism. In: Blakey RL, Whitehead VM (eds) Folates and pterins: nutritional, pharmacological and physiological aspects. New York: Wiley, 1986: 413-465.
16. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052-1059.
17. Kang S-S, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinaemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-421.
18. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-150.
19. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 1995; 7: 195-200.
20. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996; 58: 17-20.
21. Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
22. Ma J, Stamfer MJ, Heennekens CH et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-2416.
23. Molloy AM, Day S, Mills JL et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low-red cell folates; implications for folate intake recommendations. Lancet 1997; 349: 1591-1593.
24. Kang S-S, Wong PW, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458-462.
25. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevations of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988; 81: 466-174.
26. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B12, vitamin B6 and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57: 47-53.
27. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698.
28. Miller JW, Ribaya-Mercado JD, Russell RM et al. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992; 55: 1154-1160.
29. Wilcken DEL, Gupta VJ. Sulfur containing amino acids in chronic renal failure with particular reference to homocysteine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979; 9: 301-307.
30. Friedman JA, Dwyer JT. Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Nutrition Reviews 1995; 53: 197-201.
31. Chauveau P, Bernadette C, Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43: S72-77.
32. Chanarin I, Deacon R, Lumb M, Perry J. Cobalamin-folate interrelations. Blood Reviews 1989; 3: 211-251.
33. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-527.
34. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
35. Wilcken DEL, Wicken B. The pathogenesis of coronary artery disease. J Clin Invest 1976; 57: 1079-1082.
36. Robinson K (ed). Homocysteinaemia and vascular disease. Luxembourg: Commission of the European Community, 1990.
37. Selhub J, Jacques PF, Bostom AG et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995; 332: 286-291.
38. Stampfer MJ, Malinow WR, Willett WC et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
39. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidem 1995; 24: 704-709.
40. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle aged men. Lancet 1995; 346: 1395-1398.
41. Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease on a prospective Finnish population based survey. Atherosclerosis 1994; 106: 9-19.
42. Nygard O, Nordrehaug E, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
43. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 414-421.
44. Kang SS, Passen EL, Ruggie M, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993; 88: 1463-1469.
45. Gallagher PM, Meleady R, Shiels DC et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996; 94: 2154-2158.
46. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. Circulation 1996; 94: 1812-1814.
47. Adams M, Smith PD, Martin D, Thompson JR, Lodwick D, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. Quart J Med 1996; 89: 437-444.
48. Brattström L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-57.
49. Amundsen T, Ueland PM, Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 1995; 15: 1321-1323.
50. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-1083.
51. Fermo I, Vigano, D'Angelo S et al. Prevalence of moderate hyperhomocysteinaemia in patients with early onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753.
52. den Heijer M, Blom HJ, Gerrits W B J et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-885.
53. den Heijer M, Koster T, Blom HJ et al. Hyperhomocysteinaemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.
54. Simioni P, Prandoni P, Burilina A et al. Hyperhomocysteinemia and deep-vein thrombosis. A case control study. Thromb Haemost 1996; 76: 883.
55. Leibman HA, Sutherland D, McGehee W. A common mutation in methylenetetrahydrofolate reductase is associated with an increased risk of venous thrombosis. Thromb Haemost 1997; Supplement: 568.
56. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677 to Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818-821.
57. Rosendaal FR, Kluijtmans LAJ, den Heijer M, Heil SG, Reitsma PH, Blom MJ. MTHFR variant (thermolabile methylenetetra-hydrofolatereductase), factor V Leiden, and the risk of deep-venous thrombosis. Thromb Haemost 1997; Supplement: 569.
58. Perry DJ, Riddell AF, Pasi KJ. TL-MTHFR and venous thromboembolic disease. Thromb Haemost 1997; Supplement: 568.
59. Missiaglia E, Tosetto A, Rodeghiero F. The VITA project: risk of venous thromboembolism and C677T mutation of the MTHFR gene. Thromb Haemost 1997; Supplement: 393.
60. De Stefano V, Chiusolo P, Paciaroni K et al. Prevalence of factor V 1691G to A and methylenetetra-hydrofolate reductase 677C to T mutated genes in patients with venous thrombosis. Thromb Haemost 1997; Supplement: 569-570.
61. Mandel H, Brenner B, Berant M et al. Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. N Engl J Med 1996; 334: 763-768.
62. Selhub J, D'Angelo A. Hyperhomocysteinemia and thrombosis: acquired conditions. Thromb Haemost 1997; 78: 527-531.
63. 506). Thromb Haemost 1997; Supplement: 570.
64. Daly ME, Roberts NJ, Beauchamp NJ, Makris M, Preston FE, Peake IR. The C677T polymorphism in the methylene tetrahydrofolate reductase gene: interaction with factor V Leiden in thrombophilia patients. Thromb Haemost 1997; Supplement: 568.
65. Legnani C, Palareti G, Sassi S et al. Hyperhomocyst(e)inemia and a common methylene-tetrahydrofolate reductase mutation (Ala 223 Val MTHFR) are not associated with a history of thrombosis in patients with inherited thrombophilia. Thromb Haemost 1997; Supplement: 568.
66. Rintelen C, Pabinger I, Lechner K, Eichinger S, Kyrle PA, Mannhalter C. No evidence for an increase of the risk of venous thrombosis in patients with factor V Leiden by the homozygous mutation in the methylenetetrahydrofolate reductase gene. Thromb Haemost 1997; Supplement: 569.
67. Salomor O, Dardik R, Zivelin A et al. Homozygous methylenetetrahydrofolate reductase thermolability (MTHFR-T) is an independent risk factor for idiopathic deep vein thrombosis. Thromb Haemost 1997; Supplement: 568-569.
68. Dudman NPB, Hicks, C, Lynch JF, Wilcken DEL, Wang J. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb 1991; 11: 663-670.
69. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular disease. Thromb Res 1980; 18: 113-121.
70. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376.
71. Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
72. Panganamala RV, Karpen CW, Merola AJ. Peroxide mediated effects of homocysteine on arterial prostacyclin synthesis. Prostaglandins Leukotrienes Med 1986; 22: 349-356.
73. Wang J, Dudman NPB, Wilcken DEL. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 1993; 70: 1047-1052.
74. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart M. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982; 16: 490-493.
75. Di Minno G, Davi G, Margaglione M et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993; 92: 1400-1406.
76. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-1333.
77. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial activator. J Clin Invest 1986; 77: 1909-1916.
78. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
79. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-1914.
80. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulphate expression in cultured porcine aortic endothelial cell membrane receptor. J Clin Invest 1993; 92: 1381-1386.
81. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-2879.
82. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Eng J Med 1974; 291: 537-543.
83. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741.
84. Harker LA, Harlan JM, Ross R. Effects of sulfinpyrazole on homocysteine induced endothelial injury and atherosclerosis in baboons. Circ Res 1983; 53: 731-739.
85. Rolland PH, Friggi A, Barlatier A et al. Hyperhomocysteinemia induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995; 91: 1161-1174.
86. Celermajer DS, Sorensen K, Ryalls M et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-858.
87. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocysteinaemia is associated with impaired endothelium dependent vasodilatation in humans. Circulation 1997; 95: 1119-1121.
88. Brattström LE, Israelsson B, Jeppson J-O, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48: 215-221.
89. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgeiter HC. Vitamin requirements for the treatment of hyperhornocysteinemia in humans. J Nutr 1994; 124: 1927-1933.
90. Boushey CJ, Beresford SSA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.